Title: | Autoantibodies against type I IFNs in patients with critical influenza pneumonia |
Author: | Zhang, Qian Pizzorno, Andrés Miorin, Lisa Bastard, Paul Gervais, Adrian Le Voyer, Tom Bizien, Lucy Manry, Jeremy Rosain, Jérémie Philippot, Quentin Goavec, Kelian Morio, Tomohiro Padey, Blandine Niubó, Jordi Gallardo Ríos, Rafaela Lau, Yu-lung Triantafyllia, Vasiliki Briones, Marisa Saker, Kahina Richard, Pascale Flores, Carlos Perlin, David S. Drolet, Beth A. Espinosa Padilla, Sara Wauters, Joost Peigue Lafeuille, Helene Valiente, Adoración El Baghdadi, Jamila Tiberghien, Pierre Balsera-manzanero, María Zins, Marie Hammarström, Lennart Queromes, Gregory Bousfiha, Ahmed A. Andreakos, Evangelos Notarangelo, Luigi D. Debette, Stéphanie Prando, Carolina Condino-neto, Antonio Dominguez Pinilla, Nerea Meyts, Isabelle Aydillo, Teresa Okamoto, Keisuke Anderson, Mark S. Soumaré, Aïcha Wroblewski, Isabelle Karamitros, Timokratis Medina, Rafael A. Kisand, Kai Ramírez Duque, Nieves Feys, Simon Romero Oraa, Laura Kuo, Chen-yen Lei, Wei-te Resnick, Igor Quintana Murci, Lluis Milner, Joshua D. García Salum, Tamara Ku, Cheng-lung Van De Beek, Diederik Hsieh, Elena W.Y. Tal, Galit Fournet, Thomas Cerba Healthcare Group Patural, Hugues Pesole, Graziano Novelli, Giuseppe Lyon Antigrippe Working Group Arias, Andrés A. Shahrooei, Mohammed Rovina, Nikoletta Rodríguez-gallego, Carlos Puel, Anne Jouanguy, Emmanuelle Vinh, Donald C. Abel, Laurent Su, Helen C. Henny, Joseph Mogensen, Trine H. Cobat, Aurélie Casari, Giorgio Slaby, Ondrej Ramaswamy, Sathishkumar Abelenda Alonso, Gabriela Morel, Pascal Fragkou, Paraskevi C. Argaud, Laurent Vanderbeke, Lore Belot, Alexandre Shcherbina, Anna Al-muhsen, Saleh Biggs, Catherine M. Bogunovic, Dusan Husebye, Eystein Planas, Anna M. Heath, James R. Von Bernuth, Horst Dufouil, Carole Hagin, David Bolze, Alexandre Boeuf, Benoit Rodríguez Gallego, Carlos Christodoulou, John Bondarenko, Anastasiia Martin, Fernando Fellay, Jacques Koltsida, Ourania Sediva, Anna Ruiz Hernandez, José Juan Jeanne, Michel Bonneaudeau, Brigitte Cannet, Dorothée Ku, Cheng-lung Etablissement Français Du Sang Study Group Froidure, Antoine Laurent, Emilie Galani, Ioanna Evdokia Pothier, Pierre Gregersen, Peter K. Lemonnier, Sylvie Carratalà, Jordi Spaan, András N. Darmon, Michael Grimbacher, Bodo Del Mar Muñoz Garcia, Maria Zawadzki, Pawel Henrickson, Sarah E. Haerynck, Filomeen O'farrelly, Cliona Morand, Patrice Rosa Calatrava, Manuel Trouillet Assant, Sophie Lachaize, Morgane Okada, Satoshi Vanker, Martti Bryceson, Yenan Ling, Yun Cooper, Megan A. Lucas, Carrie L. Maniatis, Tom Romero Vázquez, Gloria María Navarrete, Nicolás Desai, Murkesh Mansouri, Davood Castagnoli, Riccardo Zins, Marie Maródi, László Mironska, Kristina Rapti, Vasiliki Baris Feldman, Hagit Pozzetto, Bruno Renia, Laurent Tancevski, Ivan Ferres, Marcela Franco, José Luis Imai, Kohsuke Ozcelik, Tayfun Pan-hammarström, Qiang Al-mulla, Fahd Pape, Jean W. Etzioni, Amos Souweine, Bertrand Pérez de Diego, Rebeca Wauters, Joost Sánchez Céspedes, Javier Sánchez Cordero, Maria Jose Uddin, Mohammed J. Solé Violán, Jordi Perroquin, Magali Ng, Lisa F.P. Abou Tayoun, Ahmad Le Corre, Nicole Snow, Andrew L. Temel, Şehime Gülsün Tsiodras, Sotirios Tzourio, Christophe Merino Díaz, Laura Coeuret Pellicer, Mireille Notarangelo, Luigi D. Javouhey, Etienne Turvey, Stuart E. Covid Human Genetic Effort Rombauts, Alexander Zatz, Mayana Uddin, K.m. Furkan Kisand, Kai Gallian, Pierre Fievet, Nathalie Palomo, Virginia Jarvis, Erich D. Rodríguez de Castro, Felipe Ferreres, José Flaig, Amandine Pujol, Aurora Cognasse, Fabrice Sancho Shimizu, Vanessa Tiberghien, Pierre Reipi Inf Working Group Nadif, Rachel Hanna, Suhair Seppänen, Mikko R.J. Constances Cohort Goldberg, Marcel Brodin, Petter Andreakos, Evangelos Le Got, Stéphane Ozguler, Anna Quenot, Jean Pierre García Sastre, Adolfo Novelli, Antonio Cordero, Elisa Colomb, Benoit Särekannu, Karita Cupic, Anastasija Mehlal Sedkaoui, Souad Sallette, Jérôme Hernu, Romain Bustamante, Carlos D. Lina, Bruno Constantinescu, Stefan N. Halwani, Rabih Casalegno, Jean Sebastien Schwebel, Carole Salamanca Rivera, Celia Aiuti, Alessandro 3C-Dijon Study Tangye, Stuart G. Dalgard, Clifton L. Retamar Gentil, Pilar Debette, Stéphanie Hamzeh Cognasse, Hind Belot, Alexandre Abel, Laurent Soler Palacín, Pere Abad Arranz, Maria Aguilar Guisado, Manuela Meyts, Isabelle Casanova, Jean-Laurent González Granado, Luis Ignacio Butte, Manish J. Itan, Yuval Haerynck, Filomeen Escoresca Ortega, Ana |
Keywords: | Grip Pneumònia Autoanticossos Influenza Pneumonia Autoantibodies |
Issue Date: | 16-Sep-2022 |
Publisher: | Rockefeller University Press |
Abstract: | In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine. Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 x 10(-5)), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old. |
Note: | Reproducció del document publicat a: https://doi.org/10.1084/jem.20220514 |
It is part of: | Journal of Experimental Medicine, 2022, vol. 219, issue. 11 |
URI: | http://hdl.handle.net/2445/191806 |
Related resource: | https://doi.org/10.1084/jem.20220514 |
ISSN: | 1540-9538 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
|